The Role of 4G allele in Plasminogen Activator Inhibitor type-1 rs1799889 Gene as Biomarker to Thrombophilic Complication among Type 2 Diabetic Patients

  • Rowida Eljack Ibrahim Department of Hematology, Faculty of Medical Laboratory Sciences, University of Gezira, Wad Medani, Sudan
  • Khalid Abdelsamea Mohamedahmed Department of Immunology, Faculty of Medical Laboratory Sciences, University of Gezira, Wad Medani, Sudan
DOI: https://doi.org/10.31661/gmj.v11i.2447
Keywords: 4G allele, Plasminogen Activator Inhibitor type-1, rs1799889 Gene, Thrombosis, T2DM

References

Zhao L, Huang P. Plasminogen activator inhibitor-1 4G/5G polymorphism is associated with type 2 diabetes risk. Int J Clin Exp Med. 2013;6(8):632-40

https://doi.org/10.1186/1741-7015-11-1

PMid:23281898 PMCid:PMC3565939

Ibrahim RE, Ibrahim SEH, Abdalsamea K, Haj-Alzebar AB, Babiker AM, Nour BYM. Evaluation of Common Coagulation Tests in Type2 Diabetic Patients and Association with Diabetic Pre-cardiovascular Complications, Gezira State-Sudan, 2020-2021. Asian Hematology Research Journal. 2021;5(4):1-6.

Almakey EA, Makeen AM, Saeed OK, Mohamedahmed KA. Association between Adiponectin and Insulin Resistance among Sudanese Males with Type 2 Diabetes Mellitus. Chinese J Med Res. 2021;4(2):34-7.

https://doi.org/10.37515/cjmr.091X.4202

Saboor M, Moinuddin M, Ilyas S. Comparison of Platelet CD Markers between Normal Individuals and Untreated Patients with Type 2 Diabetes Mellitus. J Hematol Thromb Dis. 2013;2:123.

https://doi.org/10.4172/2329-8790.1000123

Khalaf FA, Ibrahim HR, Bedair HM, Allam MM, Elshormilisy AA, Ali ST, Gaber WM. Plasminogen activator inhibitor-1 gene polymorphism as a risk factor for vascular complications in type 2 diabetes mellitus. Egypt J Med Hum Genet. 2019;20:18.

https://doi.org/10.1186/s43042-019-0018-1

Aburto-Mejía E, Santiago-Germán D, Martínez-Marino M, Galván-Plata ME, Almeida-Gutiérrez E, López-Alarcón M, et al. Hypofibrinolytic State in Subjects with Type 2 Diabetes Mellitus Aggravated by the Metabolic Syndrome before Clinical Manifestations of Atherothrombotic Disease. BioMed Res Int. 2017;2017(2):6519704.

https://doi.org/10.1155/2017/6519704

PMid:28271069 PMCid:PMC5320378

Eriksson P, Kallin B, Van 't Hooft FM, Båvenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A. 1995;92(6):1851-5.

https://doi.org/10.1073/pnas.92.6.1851

PMid:7892190 PMCid:PMC42380

Chevilley A, Lesept F, Lenoir S, Ali C, Parcq J, Vivien D. Impacts of tissue-type plasminogen activator (tPA) on neuronal survival. Front Cell Neurosci. 2015;16(9):415.

https://doi.org/10.3389/fncel.2015.00415

PMid:26528141 PMCid:PMC4607783

Parpugga TK, Tatarunas V, Skipskis V, Kupstyte N, Zaliaduonyte-Peksiene D, Lesauskaite V. The Effect of PAI-1 4G/5G Polymorphism and Clinical Factors on Coronary Artery Occlusion in Myocardial Infarction. Dis Markers. 2015;2015:260101.

https://doi.org/10.1155/2015/260101

PMid:26273123 PMCid:PMC4529953

Nordt TK, Lohrmann J, Bode C. Regulation of PAI-1 expression by genetic polymorphisms. Impact on atherogenesis. Thromb Res. 2001;103(Suppl 1):S1-5.

https://doi.org/10.1016/S0049-3848(01)00292-4

Published
2022-08-03
How to Cite
Ibrahim, R. E., & Mohamedahmed, K. A. (2022). The Role of 4G allele in Plasminogen Activator Inhibitor type-1 rs1799889 Gene as Biomarker to Thrombophilic Complication among Type 2 Diabetic Patients. Galen Medical Journal, 11, e2247. https://doi.org/10.31661/gmj.v11i.2447
Issue
Vol. 11 (2022): 2022
Section
Letter to Editor

Copyright (c) 2022 Galen Medical Journal

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

  • Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
  • Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
  • Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).